In large human transcriptomic and sequencing datasets, a role for CD4+ T cells in enhancing immune checkpoint blocker-mediated responses in persons with melanoma and mismatch-repair-deficient colon cancers that have downregulated MHC class I was suggested. These findings revise and expand the known role of MHC class I in CD8+ T cell and natural killer cell immunity and demonstrate a previously unrecognized role in CD4+ T cell-mediated cancer and alloimmunity.

1 day ago

Journal

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)

MSI-H/dMMR

Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection (clinicaltrials.gov)

P=N/A, N=66, Recruiting, Baylor College of Medicine | Trial completion date: Oct 2025 --> May 2027 | Trial primary completion date: Oct 2025 --> Dec 2026

1 day ago

Trial completion date • Trial primary completion date

Prognostic value of systemic inflammatory and nutritional markers in patients with resectable colon cancer: a retrospective observational study. (PubMed, Am J Cancer Res)

Preoperative PNI and PLR are readily accessible, independent prognostic biomarkers for patients with resectable colon cancer. They augment traditional Tumor, Node, Metastasis staging by reflecting the critical balance between pro-tumor inflammation and host immunonutritional status within the tumor microenvironment.

1 day ago

Observational data • Retrospective data • Journal

CRP (C-reactive protein)

SELENOF and its translational inhibitor EIF4A3 are differentially expressed in colon cancer. (PubMed, Arch Biochem Biophys)

Our findings explore a novel EIF4A3-SELENOF regulatory axis in colorectal cancer. SELENOF acquires conditional prognostic significance only in the context of elevated EIF4A3, highlighting the importance of molecular interaction specificity in biomarker discovery.

1 day ago

Journal

EIF4A3 (Eukaryotic Translation Initiation Factor 4A3)

ELK1/NOL3/GRP78 axis regulates proliferation and stemness in TP53-mutant colon cancer by enhancing adaptive endoplasmic reticulum stress. (PubMed, Biochim Biophys Acta Mol Basis Dis)

The ELK1/NOL3/GRP78 axis promotes the progression of TP53-mutant colon cancer by increasing adaptive ER stress and stemness. NOL3 serves as a valuable prognostic biomarker and a potential therapeutic target.

1 day ago

Journal

TP53 (Tumor protein P53) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5)

TP53 mutation • TP53 wild-type

The cGAS-STING signaling pathway mediates pyroptosis in colonic epithelial cells and accelerates the progression of CAC. (PubMed, Exp Cell Res)

The cGAS-STING signaling pathway accelerates the progression of CAC by promoting pyroptosis in colonic epithelial cells through NLRP3/caspase-1 mediation.

1 day ago

Journal

CGAS (Cyclic GMP-AMP Synthase) • NLRP3 (NLR Family Pyrin Domain Containing 3)

Traction vs. No Traction in Colonic ESD (clinicaltrials.gov)

P=N/A, N=150, Recruiting, Baylor College of Medicine | Trial completion date: Jun 2026 --> Feb 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

1 day ago

Trial completion date • Trial primary completion date

S2107: Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (clinicaltrials.gov)

P2, N=84, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Sep 2026 | Trial primary completion date: Feb 2026 --> Sep 2026

1 day ago

Trial completion date • Trial primary completion date

BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)

BRAF V600E • BRAF V600

Opdivo (nivolumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • ABP 206 (nivolumab biosimilar)